Scarica l'app Stockscreener
4.72
0.97%
0.07
Precedente Chiudi:
$4.65
Aprire:
$4.6
Volume 24 ore:
31,788
Relative Volume:
0.13
Capitalizzazione di mercato:
$43.89M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-3.59%
1M Prestazione:
-88.33%
6M Prestazione:
-82.44%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.56
$4.79
Intervallo di 1 settimana:
$4.49
$5.00
Portata 52W:
$4.48
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Nome
Tvardi Therapeutics Inc
Settore
Industria
Telefono
(713) 489-8654
Indirizzo
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Confronta TVRD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
4.68 | 43.61M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.15 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.84 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.47 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
832.23 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.34 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-14 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-10-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-10-13 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | Iniziato | Raymond James | Outperform |
| 2025-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Iniziato | Piper Sandler | Overweight |
| 2025-05-21 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Iniziato | BTIG Research | Buy |
| 2024-06-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Downgrade | Needham | Buy → Hold |
| 2024-06-13 | Downgrade | Stifel | Buy → Hold |
| 2023-03-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Ripresa | Canaccord Genuity | Buy |
| 2021-08-03 | Iniziato | JP Morgan | Neutral |
| 2020-04-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-29 | Reiterato | Laidlaw | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2019-01-15 | Iniziato | BofA/Merrill | Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Jefferies | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-12 | Ripresa | H.C. Wainwright | Buy |
| 2018-02-12 | Aggiornamento | Janney | Neutral → Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
Mostra tutto
Tvardi Therapeutics Inc Borsa (TVRD) Ultime notizie
Will Tvardi Therapeutics Inc. stock benefit from green energy trendsWeekly Investment Recap & Weekly Return Optimization Plans - newser.com
How to interpret RSI for Tvardi Therapeutics Inc. stockTake Profit & Weekly Breakout Stock Alerts - newser.com
Heatmap analysis for Tvardi Therapeutics Inc. and competitorsWeekly Trade Review & Free Technical Confirmation Trade Alerts - newser.com
Key resistance and support levels for Tvardi Therapeutics Inc.Portfolio Growth Summary & High Accuracy Buy Signal Tips - newser.com
Understanding Tvardi Therapeutics Inc.’s price movementWeekly Trade Analysis & Fast Gaining Stock Reports - newser.com
Does Tvardi Therapeutics Inc. stock trade at a discount to peersJuly 2025 EndofMonth & Risk Controlled Stock Alerts - newser.com
What to do if you’re stuck in Tvardi Therapeutics Inc.July 2025 Pullbacks & Safe Capital Growth Stock Tips - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tvardi Therapeutics, Inc. (TVRD) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Can Tvardi Therapeutics Inc. stock deliver consistent earnings growthDip Buying & Short-Term Trading Alerts - newser.com
What data driven models say about Tvardi Therapeutics Inc.’s futureAnalyst Upgrade & Community Verified Watchlist Alerts - newser.com
Tvardi Therapeutics, Inc. (TVRD) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Why Tvardi Therapeutics Inc. stock is recommended by analystsJuly 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - newser.com
How to track smart money flows in Tvardi Therapeutics Inc.July 2025 Levels & Weekly High Return Opportunities - newser.com
How Tvardi Therapeutics Inc. stock reacts to global recession fears2025 Support & Resistance & Verified Swing Trading Watchlists - newser.com
Will Tvardi Therapeutics Inc. benefit from macro trendsJuly 2025 Review & Capital Protection Trading Alerts - newser.com
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - The AI Journal
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tvardi Therapeutics, Inc. (TVRD) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2025-10-31 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tvardi Therapeutics, Inc. (TVRD) and Encourages Stockholders to Learn More About the Investigation | NDAQ:TVRD | Press Release - Stockhouse
Using AI based signals to follow Tvardi Therapeutics Inc.2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
Is Tvardi Therapeutics Inc. stock ready for a breakoutJuly 2025 Momentum & Consistent Profit Alerts - newser.com
Using Bollinger Bands to evaluate Tvardi Therapeutics Inc.2025 Volume Leaders & Weekly Return Optimization Alerts - newser.com
Can Tvardi Therapeutics Inc. (69C) stock hold up in economic slowdownJuly 2025 Setups & Expert Curated Trade Setups - newser.com
Is Tvardi Therapeutics Inc. (69C) stock a safe buy pre earningsLong Setup & Fast Momentum Entry Tips - newser.com
Why Tvardi Therapeutics Inc. (69C) stock could outperform next year2025 Volume Leaders & Technical Confirmation Trade Alerts - newser.com
Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - The Joplin Globe
Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – TRVD - Business Wire
Bronstein, Gewirtz & Grossman, LLC Encourages Tvardi Therapeutics, Inc. (TVRD) Investors to Inquire about Securities Investigation - ACCESS Newswire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - GlobeNewswire
Tvardi Therapeutics (TVRD) Price Target Decreased by 65.50% to 20.11 - MSN
Measuring Tvardi Therapeutics Inc.’s beta against major indicesCPI Data & Community Consensus Stock Picks - newser.com
Tvardi Therapeutics Inc Azioni (TVRD) Dati Finanziari
Non sono disponibili dati finanziari per Tvardi Therapeutics Inc (TVRD). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.68%
0.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):